Caribou Biosciences (NASDAQ:CRBU) and Sorrento Therapeutics (OTCMKTS:SRNEQ) Review

Sorrento Therapeutics (OTCMKTS:SRNEQ – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both small-cap medical companies, but which is the superior business? We’ll compare the two companies based on dividend strength, valuation, earnings, profitability, analyst recommendations, risk and institutional ownership.

return

This table compares Sorrento Therapeutics and Caribou Biosciences’ net margins, return on equity and return on assets.

Analyst recommendations

This is a summary of recent ratings and price targets for Sorrento Therapeutics and Caribou Biosciences, as reported by MarketBeat.

Caribou Biosciences has a consensus target price of $11.25, indicating a potential upside of 525.00%. Given Caribou Biosciences’ higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Sorrento Therapeutics.

Insider and institutional ownership

0.0% of Sorrento Therapeutics shares are held by institutional investors. Comparatively, 77.5% of Caribou Biosciences shares are held by institutional investors. 2.6% of Sorrento Therapeutics shares are held by company insiders. Comparatively, 9.5% of Caribou Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and big money managers believe a company is poised for long-term growth.

Risk and volatility

Sorrento Therapeutics has a beta of 2.25, meaning its share price is 125% more volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.27, meaning its share price is 127 % more volatile than the S&P 500.

Earnings and Rating

This table compares the gross revenue, earnings per share and valuation of Sorrento Therapeutics and Caribou Biosciences.

Caribou Biosciences has lower revenue but higher earnings than Sorrento Therapeutics.

Summary

Caribou Biosciences beats Sorrento Therapeutics in 7 of the 11 factors compared between the two stocks.

About Sorrento Therapeutics

(Get a free report)

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapy by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody conjugate , as well as the bispecific antibody approach; and Sofusa, a drug delivery technology that delivers biologics directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as amyloidosis and graft-versus-host disease. The company is developing resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin, for the treatment of advanced cancer pain and osteoarthritis; and ZTlido, a topical lidocaine system for the treatment of post-herpetic neuralgia. It is engaged in the development of SEMDEXA, an injectable viscous gel formulation, which is a phase III study for the treatment of sciatica, a back pain pathology; SP-103, an investigational non-aqueous lidocaine system in clinical development in chronic low back pain; and SP-104, a new low-dose delayed-release formulation of naltrexone hydrochloride for the treatment of fibromyalgia. Partner with SmartPharm Therapeutics Inc. to develop a vaccine with genetically encoded antibodies to protect against COVID-19; and the Mayo Clinic for its Phase Ib pilot study using Sofusa’s lymphatic drug delivery technology to deliver Ipilimumab to melanoma patients. The company was founded in 2006 and is headquartered in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., together with its affiliate, filed a voluntary petition for Chapter 11 reorganization in the US Bankruptcy Court for the Southern District of Texas. The plan was later approved as a Chapter 11 liquidation on November 30, 2023.

About Caribou Biosciences

(Get a free report)

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, is engaged in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in Phase 1 clinical trial to treat relapsed or refractory B-cell non-Hodgkin lymphoma. The Company is also developing CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in Phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was founded in 2011 and is headquartered in Berkeley, California.

Get news and reviews for Sorrento Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sorrento Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.